Association between body mass index and breast cancer intrinsic subtypes in Japanese women

Experimental and Therapeutic Medicine

Volumn 4, Issue 3, 2012, Pages 391-396

  Kimura, Kosei ^a   Tanaka, Satoru ^a   Iwamoto, Mitsuhiko ^a   Fujioka, Hiroya ^a   Takahashi, Yuko ^a   Satou, Nayuko ^a   Uchiyama, Kazuhisa ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Body mass index; Breast cancer; Case only analysis; Intrinsic subtype; Japanese population

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; TRIPLE NEGATIVE BREAST CANCER; UNDERWEIGHT;

EID: 84863902428     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.621     Document Type: Article

References (32)

1. Masuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 39: 850-858, 2009.
2. Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D and Hisamichi S: The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 108: 901-906, 2004.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
4. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750, 2009.
5. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB and Caan BJ: Epidemiology breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11: R31, 2009.
6. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
7. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D and Ellis IO: Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42: 3149-3156, 2006.
8. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
9. Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR and Børresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7: 127, 2006.
10. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007.
11. Brown M, Tsodikov A, Bauer KR, Parise CA and Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 112: 737-747, 2008.
12. Trivers K F, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ and Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20: 1071-1082, 2009.
13. Millikan RC, Newman B, Tse CK, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123-139, 2008.
14. Phipps AI, Malone KE, Porter PL, Daling JR and Li CI: Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17: 2078-2086, 2008.
15. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16: 439-443, 2007.
16. Iwasaki M, Otani T, Inoue M, Sasazuki S and Tsugane S; for the Japan Public Health Center-Based Prospective Study Group: Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. Ann Epidemiol 17: 304-312, 2007.
17. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Shimazu T and Tsugane S; Japan Public Health Center-Based Prospective Study Group: Body weight at age 20 years, subsequent weight change and breast cancer risk defned by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer 129: 1214-1224, 2011.
18. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363: 157-163, 2004.
19. Begg CB and Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 3: 173-175, 1994.
20. Rich-Edwards JW, Goldman MB, Willett WC, Hunter DJ, Stampfer ML, Colditz GA and Manson JE: Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 171: 171-177, 1994.
21. Harvie M, Hooper L and Howell AH: Central obesity and breast cancer risk: a systematic review. Obes Rev 4: 157-173, 2003.
22. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12: 1447-1453, 2006.
23. Friedenreich CM: Review of anthropometric factor and breast cancer risk. Eur J Cancer Prev 10: 15-32, 2001.
24. Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569-578, 2008.
25. Miller WR, Hawkins RA and Forrest AP: Significance of aromatase activity in human breast cancer. Cancer Res 42: 3365s-3368s, 1982.
26. Perel E, Wilkins D and Killinger DW: The conversion of andro-stenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem 13: 89-94, 1980.
27. Sakakura T, Nishizuka Y and Dawe CJ: Capacity of mammary fat pads of adult C3H/HeMs mice to interact morphogenetically with fetal mammary epithelium. J Natl Cancer Inst 63: 733-736, 1979.
28. Sakakura T, Nishizuka Y and Dawe CJ: Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science 194: 1439-1441, 1976.
29. Shyamala G: Progesterone signaling and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia 4: 89-104, 1999.
30. Kalkhoff RK: Metabolic effects of progesterone. Am J Obstet Gynecol 142: 735-738, 1982.
31. Russo J, Hu YF, Silva ID and Russo IH: Cancer risk related to mammary gland structure and development. Microsc Res Tech 52: 204-223, 2001.
32. Prat A and Perou CM: Mammary development meets cancer genomics. Nat Med 15: 842-844, 2009.